PMID- 18436489
OWN - NLM
STAT- MEDLINE
DCOM- 20090408
LR  - 20131121
IS  - 1878-3562 (Electronic)
IS  - 1590-8658 (Linking)
VI  - 41
IP  - 2
DP  - 2009 Feb
TI  - Efficacy of Helicobacter pylori eradication therapy in chronic liver disease.
PG  - 134-40
LID - 10.1016/j.dld.2008.03.005 [doi]
AB  - BACKGROUND/AIMS: Peptic ulcers occur more commonly in patients with liver 
      cirrhosis (LC). Helicobacter pylori is recognized as the most important etiology 
      in the pathogenesis of peptic ulcers. We investigated the efficacy of proton pump 
      inhibitor (PPI)-based triple therapy in patients with chronic liver disease and 
      peptic ulcer. PATIENTS AND METHODS: One hundred sixty-three patients with LC or 
      chronic hepatitis (CH) with a peptic ulcer and proven H. pylori infection were 
      included. The combination of PPI, amoxicillin (1.0 g), and clarithromycin (500 
      mg), each given twice daily, was administered for 1 or 2 weeks. The eradication 
      of H. pylori was determined by the rapid urease test, histology, or the 13C-urea 
      breath test at least 4 weeks after completing the treatment. RESULTS: The 
      eradication rate of H. pylori was similar between the LC and CH groups; 82.6% and 
      88.1%, respectively. In addition, there were no significant differences in 
      eradication rates between the patients with Child-Pugh class A and Child-Pugh 
      class B/C disease. The side effects in each group were generally mild. Only the 
      serum ALT levels showed a significant correlation with the success of H. pylori 
      eradication in both the LC and CH groups. CONCLUSION: The PPI-based triple 
      therapy achieves high eradication rates for H. pylori infection, in patients with 
      chronic liver disease, without significant side effects.
FAU - Jung, S W
AU  - Jung SW
AD  - Division of Gastroenterology, Department of Internal Medicine, Korea University 
      College of Medicine, Ansan Hospital, 516 Gojan-dong, Danwon-gu, Ansan-si, 
      Gyeonggi-do 425-707, South Korea.
FAU - Lee, S W
AU  - Lee SW
FAU - Hyun, J J
AU  - Hyun JJ
FAU - Kim, D I
AU  - Kim DI
FAU - Koo, J S
AU  - Koo JS
FAU - Yim, H J
AU  - Yim HJ
FAU - Park, J J
AU  - Park JJ
FAU - Lee, H S
AU  - Lee HS
FAU - Chun, H J
AU  - Chun HJ
FAU - Um, S H
AU  - Um SH
FAU - Choi, J H
AU  - Choi JH
FAU - Kim, C D
AU  - Kim CD
FAU - Ryu, H S
AU  - Ryu HS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20080423
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 804826J2HU (Amoxicillin)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
CIN - Dig Liver Dis. 2009 Feb;41(2):141-2. PMID: 19112053
MH  - Adult
MH  - Alanine Transaminase/blood
MH  - Amoxicillin/therapeutic use
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Breath Tests
MH  - Clarithromycin/therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Endoscopy, Digestive System
MH  - Female
MH  - Helicobacter Infections/diagnosis/*drug therapy/*microbiology
MH  - Helicobacter pylori/*isolation & purification
MH  - Hepatitis, Chronic/*microbiology
MH  - Humans
MH  - Liver Cirrhosis/*microbiology
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/diagnosis/*drug therapy/*microbiology
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2008/04/26 09:00
MHDA- 2009/04/09 09:00
CRDT- 2008/04/26 09:00
PHST- 2007/07/14 00:00 [received]
PHST- 2008/03/03 00:00 [revised]
PHST- 2008/03/03 00:00 [accepted]
PHST- 2008/04/26 09:00 [pubmed]
PHST- 2009/04/09 09:00 [medline]
PHST- 2008/04/26 09:00 [entrez]
AID - S1590-8658(08)00106-0 [pii]
AID - 10.1016/j.dld.2008.03.005 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2009 Feb;41(2):134-40. doi: 10.1016/j.dld.2008.03.005. Epub 2008 
      Apr 23.